Publication | Closed Access

Disruption of RBMS3 suppresses PD-L1 and enhances antitumor immune activities and therapeutic effects of auranofin against triple-negative breast cancer

Cancer ImmunosurveillanceMedicineImmune ActivitiesImmunologyTumor ImmunityCell DeathTherapeutic EffectsImmune Checkpoint InhibitorBreast CancerTriple-negative Breast CancerTumor SuppressorImmunotherapyCancer BiologyCell BiologyTumor MicroenvironmentTumor Biology